文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

Namilumab或英夫利西单抗对比标准治疗用于住院COVID-19患者(CATALYST):一项随机、多中心、多臂、多阶段、开放标签、适应性、2期、概念验证试验

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
PubMed 文献 · Lancet Respir Med · 2021-12-16
一句话结论在住院COVID-19肺炎且CRP≥40 mg/L患者中,Namilumab降低炎症(CRP随时间变化)的概率为97%,英夫利西单抗仅15%;作者认为Namilumab应优先进一步研究。

CATALYST是一项在英国9家医院开展的随机、多中心、多臂、多阶段、平行组、开放标签、适应性、2期、概念验证试验,纳入年龄≥16岁、因COVID-19肺炎住院且CRP≥40 mg/L的患者,按1:1:1随机分配至常规治疗、常规治疗+单次静脉Namilumab 150 mg或常规治疗+单次静脉英夫利西单抗5 mg/kg,随机化按院内护理地点(病房vs ICU)分层。主要终点为CRP浓度随时间的变化,采用贝叶斯多层模型分析。Namilumab优于常规治疗降低CRP的概率为97%,英夫利西单抗为15%;治疗-时间交互作用点估计Namilumab为-0.09(95%CI -0.19至0.00),英夫利西单抗为0.06(95%CI -0.05至0.17)。作者结论认为Namilumab(而非英夫利西单抗)显示了降低炎症的概念验证证据,应优先进一步研究。

要点

  • Namilumab组CRP随时间下降优于常规治疗的概率为97%,英夫利西单抗组仅15%。
  • 治疗-时间交互作用点估计:Namilumab -0.09(95%CI -0.19至0.00),英夫利西单抗0.06(95%CI -0.05至0.17)。
  • Namilumab组不良事件134例(55例中30例,55%),常规治疗组145例(54例中29例,54%)。
  • 英夫利西单抗组不良事件102例(29例中20例,69%),常规治疗组112例(34例中17例,50%)。
  • 死亡:Namilumab组6例(11%)vs 常规治疗组10例(19%);英夫利西单抗组4例(14%)vs 常规治疗组5例(15%)。

适用人群与场景

  • 年龄≥16岁、因COVID-19肺炎住院且CRP≥40 mg/L的患者,来自英国9家医院。
  • 随机化按院内护理地点(病房vs ICU)分层。

诊断标准与关键阈值

  • 纳入标准:年龄≥16岁,因COVID-19肺炎住院,CRP≥40 mg/L。

处置流程与药物剂量

  • 常规治疗组:仅接受常规治疗。
  • Namilumab组:常规治疗+单次静脉Namilumab 150 mg。
  • 英夫利西单抗组:常规治疗+单次静脉英夫利西单抗5 mg/kg。

研究设计与关键结果

  • 研究类型:随机、多中心、多臂、多阶段、平行组、开放标签、适应性、2期、概念验证试验;英国9家医院;2020年6月15日至2021年2月18日筛查299例,入组146例,随机分配至常规治疗(n=54)、Namilumab(n=57)、英夫利西单抗(n=35)。
  • 主要终点(CRP随时间变化):Namilumab组52例 vs 常规治疗组45例,Namilumab优于常规治疗的概率97%,治疗-时间交互作用点估计-0.09(95%CI -0.19至0.00);英夫利西单抗组28例 vs 常规治疗组29例,优于常规治疗的概率15%,点估计0.06(95%CI -0.05至0.17)。
  • 不良事件:Namilumab组134例(55例中30例,55%)vs 常规治疗组145例(54例中29例,54%);英夫利西单抗组102例(29例中20例,69%)vs 常规治疗组112例(34例中17例,50%)。
  • 死亡:Namilumab组6例(11%)vs 常规治疗组10例(19%);英夫利西单抗组4例(14%)vs 常规治疗组5例(15%)。

证据类型、等级与局限

  • 证据类型:随机、多中心、多臂、多阶段、开放标签、适应性、2期、概念验证试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为Namilumab(而非英夫利西单抗)在住院COVID-19肺炎患者中显示了降低炎症(以CRP浓度衡量)的概念验证证据,应优先进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dysregulated inflammation is associated with poor outcomes in COVID-19. We aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise agents for phase 3 trials.

METHODS: In this randomised, multicentre, multi-arm, multistage, parallel-group, open-label, adaptive, phase 2, proof-of-concept trial (CATALYST), we recruited patients (aged ≥16 years) admitted to hospital with COVID-19 pneumonia and C-reactive protein (CRP) concentrations of 40 mg/L or greater, at nine hospitals in the UK. Participants were randomly assigned with equal probability to usual care or usual care plus a single intravenous dose of namilumab (150 mg) or infliximab (5 mg/kg). Randomisation was stratified by care location within the hospital (ward vs intensive care unit [ICU]). Patients and investigators were not masked to treatment allocation. The primary endpoint was improvement in inflammation, measured by CRP concentration over time, analysed using Bayesian multilevel models. This trial is now complete and is registered with ISRCTN, 40580903.

FINDINGS: Between June 15, 2020, and Feb 18, 2021, we screened 299 patients and 146 were enrolled and randomly assigned to usual care (n=54), namilumab (n=57), or infliximab (n=35). For the primary outcome, 45 patients in the usual care group were compared with 52 in the namilumab group, and 29 in the usual care group were compared with 28 in the infliximab group. The probabilities that the interventions were superior to usual care alone in reducing CRP concentration over time were 97% for namilumab and 15% for infliximab; the point estimates for treatment-time interactions were -0·09 (95% CI -0·19 to 0·00) for namilumab and 0·06 (-0·05 to 0·17) for infliximab. 134 adverse events occurred in 30 (55%) of 55 patients in the namilumab group compared with 145 in 29 (54%) of 54 in the usual care group. 102 adverse events occurred in 20 (69%) of 29 patients in the infliximab group compared with 112 in 17 (50%) of 34 in the usual care group. Death occurred in six (11%) patients in the namilumab group compared with ten (19%) in the usual care group, and in four (14%) in the infliximab group compared with five (15%) in the usual care group.

INTERPRETATION: Namilumab, but not infliximab, showed proof-of-concept evidence for reduction in inflammation-as measured by CRP concentration-in hospitalised patients with COVID-19 pneumonia. Namilumab should be prioritised for further investigation in COVID-19.

FUNDING: Medical Research Council.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Fisher BA, Veenith T, Slade D, et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2021. PMID: 34922649. doi:10.1016/S2213-2600(21)00460-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。